Abcuro

Abcuro is a company founded in 2018 headquartered in the United States. Its most recent tracked round is Series C+. Brouky classifies it under Software & Developer Tools. Brouky records 4 investors associated with the company.

Abcuro is a clinical-stage biotechnology company developing therapies for autoimmune diseases and cancer through precise modulation of cytotoxic T cells. Its lead candidate, ulviprubart (ABC008), is a first-in-class monoclonal antibody targeting killer cell lectin-like receptor G1 (KLRG1), designed to selectively deplete highly cytotoxic T cells implicated in tissue damage.